modalis

Modalis is a Waltham MA/Tokyo based biotech company developing gene therapies for rare diseases with a novel CRISPR based epigenome editing technology.

[modalis @modalistx]

Meeting Justin and his family was both inspiring and humbling. His curiosity, intellect, and determination strengthened our resolve to advance new treatment options for individuals and families living with LAMA2-RD. #LAMA2
https://t.co/EKEBr5VS6T

[modalis @modalistx]

Modalis Receives Donation from Swiss Patient Organization “Emily’s Future is Now”

Let’s fight this disease together !

https://t.co/P6y7TVciJj

[modalis @modalistx]

Modalis Announces Publication in Human Gene Therapy of Study Demonstrating Efficient LAMA1 Gene Activation for the Treatment of LAMA2-CMD - https://t.co/lkLmr7yEOt

[modalis @modalistx]

We are thrilled to announce a strategic partnership with SOLVE FSHD, along with successful strategic funding dedicated to advancing our MDL-103 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

[modalis @modalistx]

Modalis has been selected as a finalist in the XPRIZE Healthspan FSHD Bonus Prize Competition and awarded research funds. #xprize
https://t.co/2uthVL1VTx

[modalis @modalistx]

Happy New Year 2025!
Excited to announce the new chapter of the collaboration!

[modalis @modalistx]

Modalis Therapeutics has received an Orphan Drug Designation from the U.S. Food and Drug Administration for MDL-101, a treatment for congenital muscular dystrophy type 1A (LAMA2-CMD).

[modalis @modalistx]

FDA Grants Rare Pediatric Disease Designation to MDL-101 for the treatment of congenital muscular dystrophy type 1a (LAMA2-CMD)

[modalis @modalistx]

MODALIS to present its development progress at the Genome Editing Tx Summit.

[modalis @modalistx]

Modalis will present process development data at the 16th Annual Bioprocessing Summit on Aug 20th.

[modalis @modalistx]

Our development efforts towards LAMA2-CMD were featured.

https://t.co/tnFbJQlBHX

[modalis @modalistx]

Excited to share that a paper has been published on preclinical data from our lead program, MDL-101 !

https://t.co/nGOrvU9aOW

[modalis @modalistx]

MODALIS to present MDL-101 data at 4th Next Generation Gene Therapy Vector conference.

[modalis @modalistx]

Modalis announced our collaboration with Ginkgo Bioworks. Epigenome editing meets Synthetic Biology and the world-leading biofoundry capabilities!
https://t.co/u6ezfOvKUH

[modalis @modalistx]

We are excited to announce that MODALIS' mini-Cas9 patent has been granted in Japan.

https://t.co/gzM1RwIYEo

[modalis @modalistx]

Modalis announced research collaboration with JCR pharma, a rare disease company, on an undisclosed CNS target.
https://t.co/cTdgmlgIVY

[modalis @modalistx]

Our scientist, John, is participating as one of the panel for the webinar.
https://t.co/6cw1fx4Klz

[modalis @modalistx]

MODALIS is the sole company to put both ACTIVATION and SUPPRESSION into practical use.

https://t.co/f2AlBMOC1l

[modalis @modalistx]

Modalis to present at #asgct next week. See you in DC.

[modalis @modalistx]

https://t.co/dp7NcfcMyh